CDKN2A and central nervous system cancer: Both CDKN2A gene products, p14 and p16, can inhibit angiogenesis in glioma cells by upregulating tissue inhibitor of metalloproteinase‐3 or downregulating vascular endothelial growth factor, respectively [27, 31], indicating that the loss of CDKN2A may promote blood vessel growth in vivo.